FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:535-544 August 9, 2007 Number 6 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Roosendaal, G. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Effective ways to prevent arthropathy in severe hemophilia are unknown.

Methods We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI).

Results Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups.

Conclusions Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov] .)

Source Information

Authors' affiliations are listed in the Appendix.

Address reprint requests to Dr. M.J. Manco-Johnson, Mountain States Regional Hemophilia and Thrombosis Center, MS F-416, PO Box 6507, Aurora, CO 80045, or at marilyn.manco-johnson{at}uchsc.edu.

Full Text of this Article

Related Letters:

Prophylaxis vs. Episodic Treatment to Prevent Joint Disease in Severe Hemophilia
Bernstein M. J., Manco-Johnson M. J., Riske B., the Joint Outcome Study Authors
Extract | Full Text | PDF  
N Engl J Med 2007; 357:2087-2088, Nov 15, 2007. Correspondence

This article has been cited by other articles:

• Baud'huin, M., Duplomb, L., Teletchea, S., Charrier, C., Maillasson, M., Fouassier, M., Heymann, D. (2009). Factor VIII-von Willebrand Factor Complex Inhibits Osteoclastogenesis and Controls Cell Survival. J. Biol. Chem. 284: 31704-31713 [Abstract] [Full Text]  
• Ross, C., Goldenberg, N. A., Hund, D., Manco-Johnson, M. J. (2009). Athletic Participation in Severe Hemophilia: Bleeding and Joint Outcomes in Children on Prophylaxis. Pediatrics 124: 1267-1272 [Abstract] [Full Text]  
• Mancuso, M. E., Berardinelli, L., Beretta, C., Raiteri, M., Pozzoli, E., Santagostino, E. (2009). Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. haematol 94: 687-692 [Abstract] [Full Text]  
• Kempton, C. L., White, G. C. II (2009). How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 113: 11-17 [Abstract] [Full Text]  
• Sun, J., Hakobyan, N., Valentino, L. A., Feldman, B. L., Samulski, R. J., Monahan, P. E. (2008). Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood 112: 4532-4541 [Abstract] [Full Text]  
• Collins, P., Faradji, A., Morfini, M., Enriquez, M. M., Gorina, E., Schwartz, L., Lemm, G. (2008). Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study. ASH ANNUAL MEETING ABSTRACTS 112: 516-516 [Abstract]  
• Manco-Johnson, M. J., Wang, C., Konkle, B. A., Ingram-Rich, R., Humes, S., Soucie, J. M. (2008). Primary Prophylaxis Prevents the Onset of Arthropathy: Longitudinal Results of 603 Boys with Severe Factor VIII Deficiency Analyzed through the Centers for Disease Control Universal Data Collection (CDC UDC) Study.. ASH ANNUAL MEETING ABSTRACTS 112: 3392-3392 [Abstract] [Full Text]  
• Lacroix-Desmazes, S., Navarrete, A.-M., Andre, S., Bayry, J., Kaveri, S. V., Dasgupta, S. (2008). Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 112: 240-249 [Abstract] [Full Text]  
• Bernstein, M. J., Manco-Johnson, M. J., Riske, B., the Joint Outcome Study Authors, (2007). Prophylaxis vs. Episodic Treatment to Prevent Joint Disease in Severe Hemophilia. NEJM 357: 2087-2088 [Full Text]  
• Roosendaal, G., Lafeber, F. (2007). Prophylactic Treatment for Prevention of Joint Disease in Hemophilia -- Cost versus Benefit. NEJM 357: 603-605 [Full Text]